Solid Biosciences
SLDB

Solid Biosciences (SLDB) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
Cantor FitzgeraldMaintainedOverweight$26.00 from $16.00Aug 27, 2026
Truist SecuritiesMaintainedBuy$20.00 from $16.00Aug 21, 2026
HC Wainwright & Co.MaintainedBuy$25.00 from $20.00Jun 3, 2026
WedbushMaintainedOutperform$16.00May 18, 2026
Piper SandlerMaintainedOverweight$18.00 from $17.00May 13, 2026
WedbushMaintainedOutperform$16.00 from $17.00May 13, 2026
JP MorganMaintainedOverweight$12.00 from $11.00Mar 25, 2026
HC Wainwright & Co.MaintainedBuy$20.00Mar 23, 2026
NeedhamMaintainedBuy$19.00Mar 20, 2026
Chardan CapitalMaintainedBuy$15.00Mar 20, 2026
GuggenheimInitiated CoverageBuy$26.00Mar 20, 2026
Chardan CapitalMaintainedBuy$15.00Mar 12, 2026
WedbushMaintainedOutperform$17.00 from $14.00Mar 12, 2026
WedbushMaintainedOutperform$14.00Mar 11, 2026
NeedhamMaintainedBuy$16.00Feb 9, 2026
NeedhamMaintainedBuy$16.00Jan 14, 2026
NeedhamInitiated CoverageBuy$16.00Dec 4, 2025
JP MorganMaintainedOverweight$11.00 from $13.00Nov 5, 2025
CitigroupMaintainedBuy$14.00 from $16.00Nov 5, 2025
Chardan CapitalMaintainedBuy$15.00Nov 4, 2025

Frequently asked questions

  • What is the latest analyst rating on SLDB?

    On Aug 27, 2026, Cantor Fitzgerald maintained Solid Biosciences at Overweight with a price target of $26.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.